Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
NEW YORK, March 02, 2017 -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.
| Ohr Pharmaceutical Presentation Details | |
| Date: | Monday, March 6 |
| Time: | 4:40pm Eastern Time |
| Location: | Regis Ballroom, 3rd Floor |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
